State Street
PCVX icon

State Street’s Vaxcyte PCVX Stock Holding History

State Street’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$311M Buy
5,351,698
+911,179
+21% +$49.5M 0.01% 796
2026
Q1 		$258M Sell
4,440,519
-539,486
-11% -$29.3M 0.01% 826
2025
Q4 		$230M Buy
4,980,005
+194,116
+4% +$8.68M 0.01% 868
2025
Q3 		$172M Sell
4,785,889
-156,346
-3% -$5.18M 0.01% 1026
2025
Q2 		$161M Buy
4,942,235
+534,552
+12% +$17.5M 0.01% 1042
2025
Q1 		$166M Sell
4,407,683
-131,723
-3% -$10.5M 0.01% 997
2024
Q4 		$372M Buy
4,539,406
+1,133,663
+33% +$113M 0.01% 627
2024
Q3 		$389M Buy
3,405,743
+38,596
+1% +$3.48M 0.02% 600
2024
Q2 		$254M Buy
3,367,147
+30,055
+0.9% +$2.05M 0.01% 738
2024
Q1 		$228M Sell
3,337,092
-52,436
-2% -$3.63M 0.01% 810
2023
Q4 		$213M Buy
3,389,528
+244,269
+8% +$12.7M 0.01% 807
2023
Q3 		$160M Sell
3,145,259
-18,053
-0.6% -$891K 0.01% 886
2023
Q2 		$158M Buy
3,163,312
+87,296
+3% +$4.14M 0.01% 929
2023
Q1 		$115M Sell
3,076,016
-91,965
-3% -$3.9M 0.01% 1087
2022
Q4 		$152M Buy
3,167,981
+1,174,945
+59% +$46.1M 0.01% 907
2022
Q3 		$47.8M Buy
1,993,036
+137,392
+7% +$3.48M ﹤0.01% 1620
2022
Q2 		$40.4M Buy
1,855,644
+471,476
+34% +$10.9M ﹤0.01% 1791
2022
Q1 		$33.4M Buy
1,384,168
+209,237
+18% +$4.57M ﹤0.01% 2025
2021
Q4 		$28M Buy
1,174,931
+38,677
+3% +$900K ﹤0.01% 2221
2021
Q3 		$28.8M Sell
1,136,254
-367,009
-24% -$8.9M ﹤0.01% 2211
2021
Q2 		$33.8M Sell
1,503,263
-268,813
-15% -$5.5M ﹤0.01% 2131
2021
Q1 		$35M Buy
1,772,076
+850,246
+92% +$21.4M ﹤0.01% 1999
2020
Q4 		$24.5M Buy
921,830
+647,789
+236% +$24.1M ﹤0.01% 2119
2020
Q3 		$13.5M Buy
+274,041
New +$10.9M ﹤0.01% 2263

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street's PCVX Position: Q2 2026 in Review

State Street increased its Vaxcyte (PCVX) stake by 21% in Q2 2026, buying an estimated $49.5M and bringing the position to 5,351,698 shares worth $311M. The position accounts for 0.01% of the portfolio, ranked #796.

State Street first reported a position in PCVX in Q3 2020 and has held it in 24 quarters since. The position peaked at $389M in Q3 2024. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • State Street held 5,351,698 shares of Vaxcyte worth $311M as of Q2 2026.
  • State Street bought 911,179 Vaxcyte shares in Q2 2026, an estimated $49.5M.
  • Vaxcyte made up 0.01% of State Street's portfolio in Q2 2026, its #796 holding.
  • State Street first reported a position in Vaxcyte in Q3 2020 and has held it in 24 quarters since.
  • State Street's Vaxcyte position peaked at $389M in Q3 2024.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.